港股異動 | 四環醫藥(0460.HK)大漲近16% 腦卒中重磅藥克林澳臨牀數據
格隆匯8月21日丨四環醫藥(0460.HK)漲幅擴大至15.91%創6個月新高,報1.02港元,暫成交5692萬港元,最新總市值96.5億港元。四環醫藥午間表示:腦卒中重磅藥克林澳,SCI公佈良好臨牀數據。這意味着四環醫藥的馬來酸桂哌齊特(克林澳)能夠有效治療腦卒中,並有效降低患者的致殘率,未來有望進入醫保為更多患者帶來福音。據Frost&Sullivan數據顯示,2018年我國腦卒中患病人數已達1,600萬人以上。此外,日前聯營公司北京鋭業獲得新增投資方增資,加速產能擴張。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.